We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: ASCO: Durvalumab plus FLOT useful for resectable gastric, GE junction most cancers
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > ASCO: Durvalumab plus FLOT useful for resectable gastric, GE junction most cancers
ASCO: Durvalumab plus FLOT useful for resectable gastric, GE junction most cancers
Health

ASCO: Durvalumab plus FLOT useful for resectable gastric, GE junction most cancers

Last updated: June 5, 2025 6:55 pm
Editorial Board Published June 5, 2025
Share
SHARE

For sufferers with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) yields higher event-free survival outcomes than FLOT alone, in accordance with a research revealed on-line June 1 within the New England Journal of Medication. The analysis was revealed to coincide with the annual assembly of the American Society of Medical Oncology, held from Could 31 to June 4 in Chicago.

Yelena Y. Janjigian, M.D., from Memorial Sloan Kettering Most cancers Middle and Weill Cornell Medication in New York Metropolis, and colleagues performed a section 3, double-blind, randomized trial involving sufferers with resectable gastric or gastroesophageal junction adenocarcinoma. Individuals have been randomly assigned to obtain durvalumab (1,500 mg) or placebo each 4 weeks plus FLOT for 4 cycles, adopted by 10 cycles of durvalumab or placebo each 4 weeks (474 sufferers to every group). Occasion-free survival was the first finish level.

The researchers discovered that the two-year event-free survival was 67.4% and 58.5% amongst these within the durvalumab and placebo teams, respectively (hazard ratio for occasion or loss of life: 0.71; 95% confidence interval, 0.58 to 0.86; P placebo teams, respectively (relative threat: 2.69; 95% confidence interval, 1.86 to three.90).

“This is a major step forward for patients facing this difficult diagnosis,” Janjigian stated in an announcement. “To be able to tell a patient that their cancer has completely responded to treatment—and that they are cured—is one of the most rewarding moments in oncology. These results bring us closer to making that outcome a reality for many more patients worldwide.”

A number of authors disclosed ties to biopharmaceutical firms, together with AstraZeneca, which manufactures durvalumab and funded the trial.

Extra info:
Yelena Y. Janjigian et al, Perioperative Durvalumab in Gastric and Gastroesophageal Junction Most cancers, New England Journal of Medication (2025). DOI: 10.1056/NEJMoa2503701

Extra Data

Quotation:
ASCO: Durvalumab plus FLOT useful for resectable gastric, GE junction most cancers (2025, June 5)
retrieved 5 June 2025
from https://medicalxpress.com/information/2025-06-asco-durvalumab-flot-beneficial-resectable.html

This doc is topic to copyright. Aside from any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.

You Might Also Like

Scientists uncover the hyperlink between estrogen and coronary heart well being in ladies

Stopping heat-related sickness in kids as temperatures rise

AI-powered digital staining of biopsies for transplant diagnostics

New examine maps 4 key pathways to Alzheimer’s illness

A mathematical perspective presents perception into the placenta’s position and functioning

TAGGED:AscobeneficialCancerDurvalumabFLOTgastricjunctionresectable
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
Weinstein accuser Kaja Sokola rips protection lawyer: ‘You should be ashamed of yourself’
New York

Weinstein accuser Kaja Sokola rips protection lawyer: ‘You should be ashamed of yourself’

Editorial Board May 14, 2025
Folks with sure coronary heart circumstances might be able to play aggressive sports activities
Biden Rejects Trump’s Claim of Privilege for White House Visitor Logs
Most cancers analysis in your laptop computer? New synthetic intelligence mannequin makes it attainable
Yankees proceed to strand ghost runners on the street in extra-inning loss to Mariners

You Might Also Like

‘Chaotic and deeply horrifying’: As soon as a world gold commonplace, US authorities well being steering is falling aside
Health

‘Chaotic and deeply horrifying’: As soon as a world gold commonplace, US authorities well being steering is falling aside

July 7, 2025
How physique mass index impacts breast most cancers threat in postmenopausal ladies with and with out heart problems
Health

How physique mass index impacts breast most cancers threat in postmenopausal ladies with and with out heart problems

July 7, 2025
Tracing dormant most cancers cells: Chemotherapy spurs awakening, however senolytic medicine might forestall relapse
Health

Tracing dormant most cancers cells: Chemotherapy spurs awakening, however senolytic medicine might forestall relapse

July 7, 2025
Cerebral cortex synapses transmit indicators extra reliably than these in rear mind areas
Health

Cerebral cortex synapses transmit indicators extra reliably than these in rear mind areas

July 7, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?